Abstract
Chemotherapy (CTX) is essential for cancer treatment, yet its cytotoxic properties pose significant risks to clinicians. As cancer incidence rises, demand for safe and reliable CTX preparation methods intensifies; Automated Drug Compounding (ADC) promises to address these issues. Nonetheless, technical and operational barriers limit adoption. Foremost, the reliable manipulation of syringes by robotic end effectors remains a challenge. This paper examines limitations of current end effectors for ADC systems, identifies design requirements necessary, and proposes a novel design to address them.
| Original language | English |
|---|---|
| Pages (from-to) | 3287-3296 |
| Number of pages | 10 |
| Journal | Proceedings of the Design Society |
| Volume | 6 |
| Early online date | 2 Jul 2026 |
| DOIs | |
| Publication status | Published - 31 Aug 2026 |
| Event | 19th International Design Conference, DESIGN 2026 - Dubrovnik, Croatia Duration: 18 May 2026 → 26 May 2026 |
Funding
The work presented within this paper has been undertaken as part of UKRI grant EP/X025470/ and EP/X525650/1.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- automated drug compounding
- autonomous systems
- early design phase
- healthcare design
ASJC Scopus subject areas
- Software
- Modelling and Simulation
- Computer Science Applications
- Computer Graphics and Computer-Aided Design
Fingerprint
Dive into the research topics of 'Design and prototyping exploration of an end effector for automated drug compounding'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS